KIDS
Company Description
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.35M | 204.73M | 148.73M | 122.29M | 98.05M | 71.08M | 72.55M | 57.56M | 45.62M | 37.30M | 31.00M | 23.68M |
| Net Income | (39.65M) | (37.82M) | (20.97M) | 1.26M | (16.26M) | (32.94M) | (13.73M) | (12.03M) | (8.93M) | (6.57M) | (7.89M) | (9.55M) |
| EPS | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -1.18 | -0.96 | -1.85 | -0.87 | -1.05 | -1.28 |
| Free Cash Flow | (15.96M) | (41.31M) | (46.03M) | (31.80M) | (29.07M) | (29.83M) | (29.86M) | (21.05M) | (13.76M) | (5.87M) | N/A | N/A |
| FCF / Share | -0.68 | -1.79 | -2.03 | -1.54 | -1.51 | -1.65 | -2.04 | -1.67 | -2.86 | -0.78 | N/A | N/A |
| Operating CF | (4.85M) | (27.05M) | (27.05M) | (21.77M) | (13.06M) | (18.53M) | (17.77M) | (15.58M) | (7.22M) | (1.12M) | N/A | N/A |
| Total Assets | 508.63M | 473.21M | 438.75M | 427.73M | 308.40M | 324.83M | 194.56M | 112.11M | 82.30M | 30.68M | N/A | N/A |
| Total Debt | 99.99M | 80.90M | 10.06M | 907,000 | 28.51M | 26.52M | 26.25M | 21.27M | 25.45M | 17.54M | N/A | N/A |
| Cash & Equiv | 19.56M | 43.82M | 31.05M | 8.99M | 9.01M | 30.13M | 70.78M | 60.69M | 42.58M | 1.61M | N/A | N/A |
| Book Value | 346.60M | 354.57M | 377.02M | 378.65M | 225.37M | 234.77M | 142.36M | 81.73M | 47.49M | 5.99M | N/A | N/A |
| Return on Equity | -0.11 | -0.11 | -0.06 | 0.00 | -0.07 | -0.14 | -0.10 | -0.15 | -0.19 | -1.10 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.36M | 61.60M | 61.25M | 61.08M | 52.41M | 52.67M | 54.57M | 52.80M | 44.69M | 37.61M | 39.97M | 39.56M |
| Net Income | (10.69M) | (10.10M) | (11.77M) | (7.11M) | (10.66M) | (16.07M) | (7.92M) | (6.03M) | (7.80M) | (6.69M) | (4.59M) | (2.89M) |
| EPS | -0.45 | -0.43 | -0.50 | -0.30 | -0.46 | -0.69 | -0.34 | -0.26 | -0.34 | -0.29 | -0.20 | -0.13 |
| Free Cash Flow | (5.05M) | 9.75M | (3.42M) | (13.91M) | (8.38M) | (3.73M) | (11.66M) | (13.12M) | (13.15M) | (13.48M) | (11.15M) | (10.00M) |
| FCF / Share | -0.21 | 0.41 | -0.15 | -0.60 | -0.36 | -0.16 | -0.50 | -0.57 | -0.58 | -0.59 | -0.49 | -0.44 |
| Operating CF | (3.29M) | 10.35M | (581,000) | (10.46M) | (4.16M) | (3.99M) | (10.28M) | (6.43M) | (6.69M) | (7.54M) | (8.67M) | (4.37M) |
| Total Assets | 502.19M | 508.63M | 493.49M | 503.61M | 470.25M | 473.21M | 489.29M | 430.76M | 437.19M | 438.75M | 432.44M | 434.87M |
| Total Debt | 106.28M | 99.99M | 99.34M | 97.17M | 73.19M | 80.90M | 79.24M | 14.10M | 12.54M | 10.06M | 800,000 | 1.26M |
| Cash & Equiv | 14.24M | 19.56M | 16.83M | 44.55M | 33.44M | 43.82M | 51.05M | 28.93M | 21.60M | 31.05M | 10.64M | 9.71M |
| Book Value | 338.71M | 346.60M | 349.31M | 355.51M | 347.15M | 354.57M | 370.92M | 371.29M | 370.58M | 377.02M | 374.33M | 380.31M |
| Return on Equity | -0.03 | -0.03 | -0.03 | -0.02 | -0.03 | -0.05 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
